AIM ImmunoTech Inc
Biotechnology
AIM ImmunoTech Inc (AIM) Stock News
The latest AIM headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
AIMEI HEALTH TECHNOLOGY CO., LTD. ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH UNITED HYDROGEN GROUP INC.
Aimei Health Technology Co., Ltd. announced the termination of its Business Combination Agreement with United Hydrogen Group Inc. on July 7, 2026, due to failure to close the transaction by the outside date specified in the agreement. The company expressed confidence in identifying future transaction opportunities.
- GlobeNewswire Inc.·Neutral
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
AIM ImmunoTech Inc. announced a $2.4 million financing consisting of a registered direct offering of 7.5 million shares at $0.325 per share and concurrent private placement of Series I Warrants to purchase 15 million shares. The company plans to use proceeds for manufacturing clinical drug supply, Phase 3 clinical trial activities, and working capital. The offering is expected to close on May 21, 2026.